Phase 1, Open-label, Safety And Feasibility Study Of Implantation Of Pf-05206388 (Human Embryonic Stem Cell Derived Retinal Pigment Epithelium (Rpe) Living Tissue Equivalent) In Subjects With Acute Wet Age Related Macular Degeneration And Recent Rapid Vision Decline
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 06 Nov 2019
Price : $35 *
At a glance
- Drugs PF 5206388 (Primary)
- Indications Wet age-related macular degeneration
- Focus Adverse reactions; Therapeutic Use
- Sponsors Pfizer
- 17 Jun 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
- 17 Jun 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 10 Dec 2018 Planned End Date changed from 20 Nov 2018 to 1 Jun 2019.